Symbol="XRTX"
AssetType="Common Stock"
Name="XORTX Therapeutics Inc"
Description="XORTX Therapeutics Inc., a biopharmaceutical company, is dedicated to the development and commercialization of therapies to treat progressive kidney disease, hypertension, insulin resistance, and diabetic nephropathy. The company is headquartered in Vancouver, Canada."
CIK="1729214"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="SUITE 2400 - 745 THURLOW STREET, VANCOUVER, BC, CA"
FiscalYearEnd="December"
LatestQuarter="2023-03-31"
MarketCapitalization="11513400"
EBITDA="-7893947"
PERatio="None"
PEGRatio="None"
BookValue="0.504"
DividendPerShare="0"
DividendYield="0"
EPS="-0.44"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.407"
ReturnOnEquityTTM="-0.62"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.44"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="6.14"
TrailingPE="-"
ForwardPE="0.962"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.485"
EVToRevenue="-"
EVToEBITDA="-0.355"
Beta="0.182"
num_52WeekHigh="1.94"
num_52WeekLow="0.41"
num_50DayMovingAverage="0.669"
num_200DayMovingAverage="0.703"
SharesOutstanding="17989700"
DividendDate="None"
ExDividendDate="None"
symbol="XRTX"
open="0.61"
high="0.63"
low="0.60"
price="0.63"
volume="57619.00"
latest_trading_day="2023-08-08"
previous_close="0.64"
change="-0.01"
change_percent="-1.5625%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="45"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="55"
Volume_recent_avg="73644"
Change_recent_avg="0.01"
Delta_recent_avg="0.06"
Variance_recent_avg="0.03"
Change_ratio_recent_avg="-0.36"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="55"
Aroon_momentum_negative="45"
image_negative_thumbnail_id_1="516"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0089.jpeg"
image_negative_thumbnail_id_2="512"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0093.jpeg"
image_neutral_thumbnail_id_1="542"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0057.jpeg"
image_neutral_thumbnail_id_2="598"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0001.jpeg"
image_positive_thumbnail_id_1="982"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0144.jpeg"
image_positive_thumbnail_id_2="703"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0005.jpeg"
image_professor_thumbnail_id_1="1181"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0015.jpeg"
image_professor_thumbnail_id_2="1187"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0021.jpeg"
